To describe the results of a survey of members of the Society for Healthcare Epidemiology of America (SHEA) that (1) measured members' perceptions of gaps in the healthcare epidemiology knowledge base and members' priorities for SHEA research goals, (2) assessed whether members would be willing to participate in consortia to address identified gaps in knowledge, and (3) evaluated the need for training for the next generation of investigators in the field of healthcare epidemiology.
Electronic and paper survey of members of SHEA, a professional society formed to advance the science of healthcare epidemiology through research and education.
All society members were invited to participate.
Of 1,289 SHEA members, 593 (46.0%) responded. Respondents identified the following issues as important for the Research Committee of SHEA: setting the scientific agenda for healthcare epidemiology, developing collaborative infrastructure to conduct research, and developing funding mechanisms for research. Respondents ranked multidrug-resistant gram-negative organisms, antimicrobial stewardship, methicillin-resistant Staphylococcus aureus, adherence to effective hand hygiene guidelines, and Clostridium difficile infections as the most important scientific issues facing the field. Respondents ranked inadequate project funding, lack of protected time for research, and inability to obtain a grant, contract, and/or outside funding as the most significant barriers to conducting research. More than 92% of respondents support creating a SHEA research consortium; more than 40% would participate even if no additional funding were available; nearly 90% identified developing research training as a key function for SHEA.
These data provide a road map for the SHEA Research Committee for the next decade.
"Les premières alertes sont arrivées au début des années 2000 , avec, à la fin de la décennie une évolution très préoccupante. Les membres de la société américaine d'épidémiologie (SHEA) en 2009 classaient les BGN-MR comme la principale question d'actualité, avant le SARM et les infections à Clostridium difficile . En regard de cette évolution, la littérature sur la maîtrise de ces résistances est pauvre et les auteurs s'accordent sur l'absence de données solides 3—5. "
[Show abstract][Hide abstract] ABSTRACT: The incidence of extended-spectrum β-lactamase-producing Enterobacteriacae (ESBLPE) is increasing, due to the emergence of CTX-M ESBL Escherichia coli, together with the resurgence of classical ESBLPE. Carbapenemase-producing Enterobacteriaceae (CPE) rapidly disseminate in many countries, but still are emergent in France, with small outbreaks originating from repatriated patients. These multiply- or highly-resistant Gram-negative bacteria (HRGNB) pose a serious threat for the upcoming years, in the community (ESBLPE) and in the healthcare setting (ESBLPE and CPE). Contrary to MRSA, controlling the spread of ESBLPE must include strict infection control measures together with sharp decreasing of antimicrobial use. For ESBLPE, standard and contact precautions should stem their dissemination. For HRGNB, a strict control policy, similar to that applied for vancomycin-resistant enterococci (VRE), can prevent the establishment of these strains in France. Awareness is urgently needed from healthcare authorities, healthcare professionals, public and medias.
Journal des Anti-Infectieux 06/2011; 13(2). DOI:10.1016/j.antinf.2011.03.006 · 0.08 Impact Factor
[Show abstract][Hide abstract] ABSTRACT: Significant changes in the distribution of healthcare costs (away from critical care and towards chronic diseases) pose major challenges to existing healthcare systems. Caring for a patient with a chronic disease lasts as long as a person is alive, and medical expenses accumulate unrelentingly. Therefore, new approaches to disease management of chronic diseases are urgently needed, especially in terms of increasing the (currently low) rate of adherence to the patient's prescribed treatment plan. A proposal is advanced to use mobile tele-health systems to enhance the effectiveness of disease management programs. A framework to measure the ROI (return on investment) of these systems is also proposed.
Conference proceedings: ... Annual International Conference of the IEEE Engineering in Medicine and Biology Society. IEEE Engineering in Medicine and Biology Society. Conference 02/2004; 7:5367-70. DOI:10.1109/IEMBS.2004.1404498
[Show abstract][Hide abstract] ABSTRACT: The fight against multidrug-resistant (MDR) pathogens continues. This article discusses the gap between the need for new antibiotics and lean research and development (R&D) pipelines. Many large pharmaceutical companies have terminated their antibacterial research programmes as they focus on potentially more lucrative therapeutic areas. At the same time, an increasingly dry funding situation hampers smaller start-up companies. Antibacterial innovation proceeds in waves. Following a wave of broad-spectrum antibiotics in the 1980s and 1990s, many companies focused on the development of small-spectrum antibiotics targeted at Gram-positive bacteria. In recent years, MDR Gram-negative bacteria have emerged and spread rapidly. The resulting intensified need for new therapeutic options against Gram-negative bacteria appears to promise financially rewarding return on investment for pharmaceutical companies within this small market niche. Thus, interest in antibiotics, particularly in drugs effective against MDR Gram-negative bacteria, is back. We appear to be at the start of a new wave of antibacterial drug R&D that will hopefully yield new therapeutic options in the future (10-15 years). Until then, the problem of MDR Gram-negative bacteria must continue to be addressed with a multifaceted set of solutions based on currently available tools.
International journal of antimicrobial agents 03/2009; 34(1):15-20. DOI:10.1016/j.ijantimicag.2009.02.005 · 4.30 Impact Factor
Data provided are for informational purposes only. Although carefully collected, accuracy cannot be guaranteed. The impact factor represents a rough estimation of the journal's impact factor and does not reflect the actual current impact factor. Publisher conditions are provided by RoMEO. Differing provisions from the publisher's actual policy or licence agreement may be applicable.